Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Vulvo Vaginal Atrophy (VVA) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07932990
Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal Women
The goal of this clinical study was to compare Halova vaginal ovules, a non-hormonal medical device, with vaginal estriol 0.5 mg, an estrogen treatment, for genitourinary symptoms in postmenopausal women. The main questions were: * How do the treatments compare in reducing bothersome symptoms and improving vaginal health? * How do the treatments affect sexual function? * What medical problems and changes in the thickness of the lining of the uterus occur during the study? * Are improvements maintained after treatment has ended? Women willing to receive either treatment were randomly assigned to Halova or estriol in a 1:1 ratio. Women who declined hormonal therapy received Halova without randomization. Participants knew which treatment they received, while the clinicians assessing clinical outcomes did not know their treatment assignment. Participants: * Used one vaginal ovule daily for the first two weeks, then one ovule twice weekly until the end of the 12-week treatment period. * Attended assessments at baseline, Week 12, and Week 24 for symptoms, vaginal health, sexual function, safety, and the thickness of the lining of the uterus. * Received telephone monitoring at Weeks 2, 4, and 8 for treatment use, tolerability, medical problems, and satisfaction. * Received individualized menopause-related education and written materials, and completed a questionnaire about knowledge, attitudes, and behaviors at baseline and Week 12.
Gender: FEMALE
Updated: 2026-11-19
NCT06197568
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
Gender: FEMALE
Ages: 45 Years - 60 Years
Updated: 2026-10-19
1 state